超10亿美元！礼来“加码”AI+寡核苷酸技术

医药魔方Pro2025-05-01

—各奖项申报陆续启动，欢迎关注—4月29日，Creyon Bio宣布与礼来达成一项全球性许可及多靶点研究合作，共同聚焦创新靶向RNA的寡核苷酸疗法在多种疾病中的发现、开发与商业化。Creyon将利用其独特的AI驱动寡核苷酸工程化引擎，为礼来指定的靶点设计并优化候选化合物。根据协议条款，Creyon将获得1300万美元预付款，并在达成特定里程碑后，有资格获得超10亿美元的研发及商业化付款。礼来获得...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2532028635?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-05-01 09:25","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2532028635","market":"us","top_or_hot":-1,"title":"超10亿美元！礼来“加码”AI+寡核苷酸技术","media":"医药魔方Pro","content":"<div>\n<p>—各奖项申报陆续启动，欢迎关注—4月29日，Creyon Bio宣布与礼来达成一项全球性许可及多靶点研究合作，共同聚焦创新靶向RNA的寡核苷酸疗法在多种疾病中的发现、开发与商业化。Creyon将利用其独特的AI驱动寡核苷酸工程化引擎，为礼来指定的靶点设计并优化候选化合物。根据协议条款，Creyon将获得1300万美元预付款，并在达成特定里程碑后，有资格获得超10亿美元的研发及商业化付款。礼来获得...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501150846a6cfc56e&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>超10亿美元！礼来“加码”AI+寡核苷酸技术</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n超10亿美元！礼来“加码”AI+寡核苷酸技术\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-05-01 09:25 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501150846a6cfc56e&s=b><strong>医药魔方Pro</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>—各奖项申报陆续启动，欢迎关注—4月29日，Creyon Bio宣布与礼来达成一项全球性许可及多靶点研究合作，共同聚焦创新靶向RNA的寡核苷酸疗法在多种疾病中的发现、开发与商业化。Creyon将利用其独特的AI驱动寡核苷酸工程化引擎，为礼来指定的靶点设计并优化候选化合物。根据协议条款，Creyon将获得1300万美元预付款，并在达成特定里程碑后，有资格获得超10亿美元的研发及商业化付款。礼来获得...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501150846a6cfc56e&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2491050071.SGD","symbol_name":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501150846a6cfc56e&s=b","article_id":"2532028635","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501150846a6cfc56e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2532028635","pubTimestamp":1746062737,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"Creyon将利用其独特的AI驱动寡核苷酸工程化引擎，为礼来指定的靶点设计并优化候选化合物。根据协议条款，Creyon将获得1300万美元预付款，并在达成特定里程碑后，有资格获得超10亿美元的研发及商业化付款。Creyon建立了业内首个AI驱动的寡核苷酸工程引擎，能够以更系统、更具成本效益的方式设计安全、有效的寡核苷酸，超越了传统方法。QurAlis将获得4500万美元的预付款，还有资格获得高达5.77亿美元的里程款。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0238689110.USD":"贝莱德环球动力股票基金","LU1267930730.SGD":"富兰克林美国机遇基金AS Acc SGD (CPF)","LU2552382215.SGD":"WELLINGTON US BRAND POWER \"A\" (SGDHDG) ACC","SGXZ99366536.SGD":"United Global Innovation A Acc SGD-H","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU0820561909.HKD":"ALLIANZ INCOME AND GROWTH \"AM\" (HKD) INC","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU2264538146.SGD":"Fullerton Lux Funds - Global Absolute Alpha A Acc SGD","LU0820561818.USD":"安联收益及增长平衡基金Cl AM DIS","LLY":"礼来","GB00BDT5M118.USD":"天利环球扩展Alpha基金A Acc","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU2552382132.HKD":"WELLINGTON US BRAND POWER \"A\" (HKD) ACC","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU1551013342.USD":"Allianz Income and Growth Cl AMg2 DIS USD","BK4534":"瑞士信贷持仓","LU0471298694.HKD":"BGF NUTRITION \"A2\" (HKD) ACC","LU0256863811.USD":"ALLIANZ US EQUITY \"A\" INC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU0640476718.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQ \"AU\" (USD) ACC","LU2361044865.SGD":"WELLINGTON US QUALITY GROWTH \"A\" (SGDHDG) ACC","IE00BK4W5M84.HKD":"HSBC GLOBAL FUNDS ICAV US EQUITY INDEX \"HC\" (HKD) ACC","LU1712237335.SGD":"Natixis Mirova Global Sustainable Equity H-R-NPF/A SGD","SG9999018857.SGD":"United Global Quality Growth Fd Cl Acc SGD-H","SGXZ51526630.SGD":"大华环球创新基金A Acc SGD","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","BK4516":"特朗普概念","LU1093756168.USD":"FRANKLIN K2 ALTERNATIVE STRATEGIES \"A\" (USD) ACC","SGXZ31699556.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"C\" (SGDHDG) ACC","LU1069344957.HKD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (HKD) INC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU2360106947.USD":"BGF NUTRITION \"A4\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1917777945.USD":"安联专题基金Cl AT Acc","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","SG9999017495.SGD":"UGDP UNITED GLOBAL QUALITY GROWTH \"B\" (SGD) ACC","LU1035775433.USD":"AB SICAV I - AMERICAN GROWTH PORTFOLIO \"AD\" (USD) INC","LU1814569148.SGD":"WELLINGTON GLOBAL QUALITY GROWTH \"D\" (SGDHDG) ACC","SGXZ81514606.USD":"大华环球创新基金A Acc USD","LU2023250504.SGD":"Allianz Thematica Cl AMg DIS H2-SGD","LU1232071149.USD":"AZ FUND 1 GLOBAL GROWTH SELECTOR \"AAZ\" (USDHDG) ACC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC"},"translate_title":"Over $1 billion! Eli Lilly \"increases\" AI + oligonucleotide technology","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LLY":1},"content_text":"—各奖项申报陆续启动，欢迎关注—4月29日，Creyon Bio宣布与礼来达成一项全球性许可及多靶点研究合作，共同聚焦创新靶向RNA的寡核苷酸疗法在多种疾病中的发现、开发与商业化。Creyon将利用其独特的AI驱动寡核苷酸工程化引擎，为礼来指定的靶点设计并优化候选化合物。根据协议条款，Creyon将获得1300万美元预付款，并在达成特定里程碑后，有资格获得超10亿美元的研发及商业化付款。礼来获得基于各靶点的主要候选药物的独家许可，并在实现相关里程碑后，负责后续研究、开发及商业化。Creyon是一家专注于核酸药物研发的公司，致力于开发更安全、更有效的寡核苷酸疗法，旨在治疗罕见病和常见病。该公司将通过将专有的计算方法与基于适体的组织特异性递送方法相结合，开发出组织特异性的、RNA靶向的寡核苷酸疗法。Creyon建立了业内首个AI驱动的寡核苷酸工程引擎，能够以更系统、更具成本效益的方式设计安全、有效的寡核苷酸，超越了传统方法。用于精密设计药物的模块化构建模块（来源：公司官网）这不是礼来第一次涉足寡核苷酸领域：2024年9月，礼来与Genetic Leap达成合作，将利用Genetic Leap的RNA靶向药物的AI平台，为礼来选定的靶点开发寡核苷酸药物。Genetic Leap将有机会获得高达4.09亿美元总付款。2024年6月，礼来宣布与QurAlis合作，QurAlis授予礼来开发和商业化QRL-204的全球权利。QRL-204是一种潜在的first-in-class剪接开关（splice-switching）反义寡核苷酸，旨在恢复肌萎缩性侧索硬化症（ALS）、额颞叶痴呆（FTD）和其他神经退行性疾病中的UNC13A功能。QurAlis将获得4500万美元的预付款，还有资格获得高达5.77亿美元的里程款。Creyon董事长兼首席执行官Serge Messerlian表示：“我们很高兴能与礼来合作，推进我们设计的基于AI的寡核苷酸疗法。此次合作标志着Creyon公司的一个重要里程碑，我们正努力将针对罕见病和常见病的RNA靶向寡核苷酸疗法管线推进至临床试验阶段。”参考资料：[1]https://creyonbio.com/latest-news/[2]https://www.fiercebiotech.com/biotech/eli-lilly-pens-creyon-bio-ai-oligonucleotide-pact-1b-biobucks-table推荐阅读Cell突破：全新VLP递送技术来了2024年，十大制药巨头看上的AI制药公司医药魔方Pro洞察全球生物医药前沿趋势赋能中国源头创新成果转化媒体合作：15895423126Copyright © 2025 PHARMCUBE. All Rights Reserved.欢迎转发分享及合理引用，引用时请在显要位置标明文章来源；如需转载，请给微信公众号后台留言或发送消息，并注明公众号名称及ID。免责申明：本微信文章中的信息仅供一般参考之用，不可直接作为决策内容，医药魔方不对任何主体因使用本文内容而导致的任何损失承担责任。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2532028635","isCrawlerRequest":true}